{"prompt": "['2017N330177_04', 'CONFIDENTIAL', '205678', '9. Male Participants: Contraceptive use by men or women should be consistent with', 'local regulations regarding the methods of contraception for those participating in', 'clinical studies.', 'Male participants are eligible to participate if they agree to the following during the', 'intervention period and for at least 140 days:', 'Refrain from donating sperm', 'PLUS either:', 'Be abstinent from heterosexual intercourse as their preferred and usual lifestyle', '(abstinent on a long term and persistent basis) and agree to remain abstinent.', 'OR', 'Must agree to use contraception/barrier as detailed below:', 'Agree to use a male condom and female partner to use an additional highly', 'effective contraceptive method with a failure rate of <1% per year as when', 'having sexual intercourse with a woman of childbearing potential who is not', 'currently pregnant.', '10. All prior treatment-related toxicities (defined by National Cancer Institute- Common', 'Toxicity Criteria for Adverse Events (NCI-CTCAE), version 4.03 must be <Grade', '1', 'at the time of enrolment except for alopecia and Grade 2 peripheral neuropathy.', '11. In France, a participant will be eligible for inclusion in this study only if either', 'affiliated to or a beneficiary of a social security category.', 'Exclusion Criteria: Participants satisfying any of these criteria are not eligible for', 'assignment to treatment:', '1. Systemic anti-myeloma therapy within <14 days or 5 half-lives, whichever is shorter,', 'or plasmapheresis within 7 days prior to the first dose of study drug', '2. Systemic treatment with high dose steroids (equivalent to >60 mg prednisone daily', 'for >4 days) within the past 14 days if administered to treat MM or non- MM disease', '3.', 'Symptomatic amyloidosis, active POEMS syndrome (polyneuropathy,', 'organomegaly, endocrinopathy, myeloma protein, and skin changes), active plasma', 'cell leukemia at the time of screening.', '4.', 'Prior allogeneic stem cell transplant (SCT)', '5.', 'Current corneal epithelial disease except mild punctate keratopathy', '6.', 'Use of an investigational drug within 14 days or five half-lives, whichever is shorter,', 'preceding the first dose of study drug. Prior treatment with a monoclonal antibody', 'within 30 days of receiving the first dose of study drugs. Prior BCMA targeted', 'therapy.', '7.', 'Evidence of active mucosal or internal bleeding', '17']['2017N330177_04', 'CONFIDENTIAL', '205678', '8.', 'Any major surgery within the last four weeks', '9.', 'Presence of active renal condition (infection, requirement for dialysis or any other', \"condition that could affect participant's safety). Participants with isolated\", 'proteinuria resulting from MM are eligible, provided they fulfil entry criteria.', '10. Any serious and/or unstable pre-existing medical, psychiatric disorder or other', \"conditions (including lab abnormalities) that could interfere with participant's safety,\", 'obtaining informed consent or compliance to the study procedures.', '11. Current unstable liver or biliary disease per investigator assessment defined by the', 'presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or', 'gastric varices, persistent jaundice, or cirrhosis. Note: Stable chronic liver disease', \"(including Gilbert's syndrome or asymptomatic gallstones) or hepatobiliary\", 'involvement of malignancy is acceptable if participant otherwise meets entry criteria.', '12. Malignancies other than disease under study are excluded, except for any other', 'malignancy from which the participant has been disease-free for more than 2 years', 'and, in the opinion of the principal investigators and GSK Medical Monitor, will not', 'affect the evaluation of the effects of this clinical trial treatment on the currently', 'targeted malignancy (MM). Participants with curatively treated non-melanoma skin', 'cancer may be enrolled.', '13. Evidence of cardiovascular risk including any of the following:', 'a.', 'QTcF interval QTcF > 480 msec (the QT interval values must be corrected', \"for heart rate by Fridericia's formula [QTcF])\", 'b.', 'Evidence of current clinically significant uncontrolled arrhythmias, including', 'clinically significant ECG abnormalities such as 2nd degree (Type II) or 3rd', 'degree atrioventricular (AV) block.', 'c.', 'History of myocardial infarction, acute coronary syndromes (including', 'unstable angina), coronary angioplasty, or stenting or bypass grafting within', 'six months of Screening.', 'd. Class III or IV heart failure as defined by the New York Heart Association', 'functional classification system', 'e.', 'Uncontrolled hypertension', '14. Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs', 'chemically related to GSK2857916, or any of the components of the study treatment.', '15. Pregnant or lactating female.', '16. Active infection requiring antibiotic, antiviral, or antifungal treatment.', '17. Known HIV infection.', '18. Presence of hepatitis B surface antigen (HBsAg), or hepatitis B core antibody', '(HBcAb at screening or within 3 months prior to first dose of study treatment)', '19. Positive hepatitis C antibody test result or positive hepatitis C RNA test result at', 'screening or within 3 months prior to first dose of study treatment.', 'Note: Participants with positive Hepatitis C antibody due to prior resolved disease', 'can be enrolled, only if a confirmatory negative Hepatitis C RNA test is obtained.', '18']\n\n###\n\n", "completion": "END"}